Company
Ahead Together
We unite science, technology and talent to get ahead of disease together.
Purpose, strategy and culture
Innovation to prevent and treat disease is at the heart of everything we do. We aim to positively impact the health of 2.5 billion people by the end of the decade.
At a glance
GSK has a significant footprint in the US across commercial, R&D, manufacturing, and corporate functions. We employ ~15,000 people across the US and have two corporate hubs.
View our policy positions
We have policies in place across GSK to ensure we meet the high standards we set ourselves as a company, and those that are expected of us externally.
Learn more about our views and our practices across a range of issues that are important to GSK, our patients and our stakeholders.
Latest press releases
- GSK’s RSV vaccine, AREXVY, approved in US for expanded age indication in adults aged 18–49 years at increased risk
- GSK’s AREXVY associated with reductions in certain RSV-related risks including heart attack, stroke and severe flare-ups of COPD and asthma, real world study shows
- GSK awards $2M in COiMMUNITY Initiative grants to help close vaccination gaps, commits $3M for 2026
